A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Obesity, Type 2 Diabetes

In brief

The trial will enroll healthy volunteers and individuals living with obesity, with and without Type 2 Diabetes. The study, with a treatment period of up to 16 weeks in selected cohorts, will investigate GUB-UCN2 as both a standalone therapy and on top of standard of care for obesity

Key facts

Study ID

NCT07702890

Run by

Gubra A/S

People needed

188

Starts

2026-07-01

Expected to finish

2028-12-01

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Part 1
• Signed and dated informed consent obtained before any trial-related activities
• Males and female participants, aged between 18-55 years
• Body Mass Index (BMI) between 20.0 and 29.9 kg/m\^2, inclusive
• Considered generally healthy upon completion of medical history and screening safety assessments
• Part 2
• Signed and dated informed consent obtained before any trial-related activities
• Male participants, aged between 18-55 years
• Body Mass Index (BMI) between 30.0 and 35.0 kg/m\^2, inclusive
• Part 3 (participants with obesity)
• Signed and dated informed consent obtained before any trial-related activities
• Males and female participants, aged between 18-75 years
• Body Mass Index (BMI) between 30.0 and 45.0 kg/m\^2
• Part 3 (participants with T2D)
• Signed and dated informed consent obtained before any trial-related activities
• Male and female participants, aged between 18-75 years
• Body Mass Index (BMI) between 27.0 and 35.0 kg/m\^2
• Diagnosed with type 2 diabetes mellitus, HbA1c ≤ 69.0 mmol/mol (≤ 8.5%)
• Stable daily dose of antidiabetic medication

You may not qualify if…

• Known history of serious adverse reactions or serious hypersensitivity to drug or formulation excipients
• Presence or history of clinically significant gastrointestinal, cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric, malignant, metabolic, endocrinological, hematologic or venereal disorder
• Use or planned use of concomitant medication impacting the assessment of trial endpoints
• Clinically significant abnormal laboratory parameters
• Women of childbearing potential who are not using highly effective contraception

Where it is running

• PROFIL Institut fuer Stoffwechselforschung GmbH — Neuss, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.